Skip to content

Jukka Kemppainen

Chief Physician, Nuclear Medicine
Specialist in Clinical Physiology and Nuclear Medicine
M.D., Ph.D., Adj. Prof.


Finnish, Swedish, English

Work history

  • Docrates Cancer Center, Chief Physician, Nuclear Medicine 2018-
  • Turku University Hospital PET Centre, Head of Department
  • University of Turku, Subject Responsible, Clinical Physiology and Nuclear Medicine, Associate Professor/Clinical Teacher

Memberships and positions of trust

Finnish Society of Nuclear Medicine, Chairman
Scandinavian Society of Clinical Physiology and Nuclear Medicine (SSCPNM), Finnish Representative

Scientific activities

Jukka Kemppainen’s recent research has focused on the clinical applications of PET imaging in disease diagnostics. His main interests reside in the development of new PET imaging tracers for prostate cancer and PET diagnostics.


Docrates Cancer Center studied the effectiveness of 177Lu-PSMA treatment with a 4-week treatment interval for patients with metastatic castration-resistant prostate cancer under the leadership of nuclear medicine physician Jukka Kemppainen. The study involved 62 patients who had been treated with 177Lu-PSMA-617 radiopharmaceuticals at Docrates between 2017 and 2019. The study showed that a 4-week treatment interval is safe for patients and leads to good outcomes. Read more about the study here.